Sadeghi S, Groshen SG, Tsao-Wei DD, et al. - Among patients having treatment-naïve advanced or recurrent metastatic urothelial carcinoma of the bladder, ureter, or urethra not eligible for curative surgery or cisplatin-based treatment, researchers tested a gemcitabine-eribulin combination for its tolerability and efficacy in this National Cancer Institute Cancer Therapy Evaluation Program-sponsored trial. Both on days 1 and 8, participants were administered gemcitabine 1,000 mg/m² intravenously followed by eribulin 1.4 mg/m², which was then repeated in 21-day cycles until progression or unacceptable toxicity. There were 24 participants, and 12 were confirmed responders. The observed objective response rate, median overall survival, and median progression-free survival were 50%, 11.9 months, and 5.3 months, respectively. With regard to treatment response and survival in cisplatin-ineligible patients, gemcitabine-eribulin treatment resulted in favorable outcomes.